Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yadira Perez

General Practice Kissimmee, FL Medical Doctor

NPI 1881875029 CMS profile 1270509

790 Buenaventura Blvd, Kissimmee, FL 34743

Open in the dashboard

General payments

$2,110

109 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yadira Perez of Kissimmee, FL is reported in the CMS Open Payments database as having received $2,110 across 109 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $182 9
2024 General $298 15
2023 General $74 4
2022 General $320 12
2021 General $651 35
2020 General $354 19
2019 General $231 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yadira Perez
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Yadira Perez were reported at $182. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Yadira Perez General Practice median Middle half National median
2019 $231 $107 $37–$285 $163
2020 $354 $75 $25–$213 $114
2021 $651 $93 $30–$272 $132
2022 $320 $103 $36–$279 $149
2023 $74 $106 $34–$276 $160
2024 $298 $114 $39–$290 $164
2025 $182 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $339 14 payments
  2. Janssen Pharmaceuticals, Inc $258 11 payments
  3. GlaxoSmithKline, LLC. $213 12 payments
  4. Amgen Inc. $210 11 payments
  5. Lilly USA, LLC $192 10 payments
  6. AstraZeneca Pharmaceuticals LP $187 11 payments
  7. Merck Sharp & Dohme Corporation $116 6 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $91 4 payments
  9. Pfizer Inc. $91 5 payments
  10. Arbor Pharmaceuticals, Inc. $66 5 payments
  11. Other $347 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,110 109 payments
Products named General payments · program years 2019–2025
  1. XARELTO $258 11 payments
  2. VRAYLAR $197 12 payments
  3. TRELEGY ELLIPTA $173 10 payments
  4. Otezla $152 8 payments
  5. DALVANCE $123 1 payment
  6. Repatha $110 6 payments
  7. STEGLATRO $78 4 payments
  8. JANUVIA $78 4 payments
  9. TRULICITY $75 4 payments
  10. EMGALITY $75 4 payments
  11. Other $1,532 85 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 176 drugs

Part D claims

12,067

Median for General Practice: 1,105

Drug cost

$979,101

Median for General Practice: $48,734

Branded share of claims

17.9%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 137 $148,809
Jardiance Empagliflozin Brand 104 $128,493
Ozempic Semaglutide Brand 85 $116,508
Humira Adalimumab Brand 13 $96,932
Januvia Sitagliptin Phosphate Brand 41 $56,468
Trulicity Dulaglutide Brand 36 $47,543
Xarelto Rivaroxaban Brand 40 $45,048
Farxiga Dapagliflozin Propanediol Brand 30 $37,079
Janumet Sitagliptin Phos/Metformin Hcl Brand 24 $33,277
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 32 $29,624

The 10 drugs with the highest cost, of 176 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$43,290

Of which drugs: $1,230

Medicare patients

125

Average age 77

Services billed

837

77 women, 48 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Chronic kidney disease 45%
Diabetes 38%
Ischemic heart disease 34%
Depression 29%
COPD 27%
Heart failure 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 13 13 $1,064

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $30
  • Lilly USA, LLC $23
$53 104 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $53
$53 — —
Otezla
  • Amgen Inc. $46
$46 — —
Repatha
  • Amgen Inc. $46
$46 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

109 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other General Practice in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record